41 results about "Galactosidase activity" patented technology

The invention discloses an anti-aging longevity and qi-boosting soup composition and its use, comprising the following raw materials or extracts of raw materials in parts by weight: 9-30 parts of Radix Pseudostellariae, 9-30 parts of Poria, 6-20 parts of Angelicae Sinensis, 6-20 parts of stir-fried Semen Ziziphi Spinosae, 6-15 parts of Radix Ophiopogonis, 3-15 parts of roasted Polygala Tenuifolia, 10-60 parts of Longan Meat, 10-30 parts of Radix Rehmanniae, 9-30 parts of Scrophulariae, 3-20 parts of Acorus Gramineus, 9-30 parts of Semen Platycladi, 15-30 parts of roasted Plastron Tortoise, 15-30 parts of calcined Dragon Bone, 6-30 parts of Lotus, and 3-60 parts of Licorice. The composition can inhibit the activity of aging markers β-galactosidase in cells and animals, the expression of P16 or P21, remove senescent cells, improve the antioxidant capacity of cells and animals, reduce the expression level of inflammatory factors in cells and animals, and has a significant anti-aging effect.

The invention provides a high-activity beta-galactosidase mutant as well as a preparation method and application thereof. In the invention, a series of beta-galactosidase mutants are successfully obtained by analyzing a three-dimensional space structure of a compound of wild type beta-galactosidase, a substrate and metal ions and carrying out site-specific mutagenesis, combined mutagenesis and combined random mutagenesis on amino acid sites related to beta-galactosidase activity and substrate combination; and the enzymatic activity is remarkably improved.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The invention belongs to the field of food science and engineering, and discloses a preparation method of an active medicinal and edible composite nutrient AMCN with an anti-aging effect, and the preparation method comprises the following steps: putting a ganoderma lucidum monoclonal strain into a liquid culture medium for controllable culture to obtain supernate with beta-glucosidase activity of over 100mU / mL; and adding rhizoma polygonati powder, lucid ganoderma powder and mulberry leaf powder, carrying out enzymatic biotransformation, carrying out lactobacillus plantarum fermentation, adding a freeze-drying protective additive, carrying out freeze-drying, grinding to obtain the active medicinal and edible composite nutrient AMCN, and storing the finished product in a dry and dark place. The active medicinal and edible composite nutrient can be used for preparing anti-aging functional foods or nutritional health-care products. A D-galactose induced zebrafish aging model verifies that the active medicinal and edible composite nutrient prepared by the application plays an anti-aging role by relieving oxidative stress, inhibiting cell aging and maintaining telomere stability, can reduce beta-galactosidase activity and intracellular ROS (reactive oxygen species) level, improves telomerase protein concentration, and has a good anti-aging effect. And the telomere length can be effectively recovered by medium and high concentrations.

This invention discloses a method, system, device, medium, and application for constructing a diagnostic model for male infertility, belonging to the fields of male infertility diagnosis, drug screening, and assisted reproductive technology. In this invention, by simultaneously and quantitatively analyzing the pH value, mitochondrial G-quadruplex structure level, and β-galactosidase activity within a single sperm cell, and integrating routine clinical sperm testing parameters and age, a high-precision diagnostic model for male infertility and a drug screening system are established, providing a reference for assisted reproduction to meet practical needs.

The present invention relates to use of an enzyme that cleaves both alpha- and beta-1,4-glycosidic bonds and, more particularly, the present invention provides α-L-fucosidase which has α-1,4-glucosidase and β-1,4-galactosidase activities and thus is capable of producing glucose and / or galactose, which are monosaccharides, from non-fucosylated saccharides. The enzyme has transglycosylation activity and thus produces maltooligosaccharides having a higher degree of polymerization than maltooligosaccharides used as a substrate, thereby being applicable to the development of high-value-added new materials in the food industry.

This invention relates to the field of anti-aging drug technology, specifically to the application of small molecule compounds in the preparation of anti-aging drugs. These small molecule compounds competitively block the interaction between KDM6A and the vacuolar ATPase V0 domain subunit ATP6V0C by targeting a specific small molecule binding pocket of the histone demethylase KDM6A, thereby inhibiting the demethylation activity of KDM6A on lysine residue 36 of ATP6V0C. These small molecule compounds can effectively downregulate aging-related β-galactosidase activity, improve cell cycle arrest, and reverse the senescent phenotype of nerve cells induced by the environmental pollutant GenX, making them particularly suitable for combating premature aging of nerve cells induced by perfluorinated and polyfluoroalkyl compounds such as GenX. This technical solution can solve the technical problem of the lack of drugs with clearly defined components, a clear mechanism of action, stable efficacy, and the ability to specifically alleviate aging in existing technologies, and has ideal prospects for widespread application.

This invention discloses a collagen tripeptide composition, its preparation method, and its application, belonging to the field of food technology. The collagen tripeptide composition comprises the following raw materials in parts by weight: 80-200 parts of ray collagen peptide, 70-120 parts of collagen tripeptide, 100-300 parts of French flower and fruit powder, 300-600 parts of prickly pear powder, 300-500 parts of sage extract, 100-150 parts of tremella polysaccharide, 300-500 parts of wolfberry powder, and 100-300 parts of astragalus powder. The collagen tripeptide composition of this invention can reduce β-galactosidase activity, exhibiting a good anti-aging effect. Applying the collagen tripeptide composition of this invention can quickly replenish collagen and maintain skin elasticity.

The invention relates to the technical field of anti-aging drugs, in particular to application of a small molecule compound in preparation of anti-aging drugs. The small molecule compound competitively blocks the interaction between the KDM6A and a vacuolar ATP enzyme V0 structural domain subunit ATP6V0C through a specific small molecule binding pocket of targeted histone demethylase KDM6A, and further inhibits the demethylation activity of the KDM6A on 36th lysine of the ATP6V0C. The small molecule compound can effectively down-regulate the activity of senescence-related beta-galactosidase, improve cell cycle arrest and reverse nerve cell senescence phenotypes induced by environmental pollutant GenX, and is especially suitable for resisting nerve cell premature senescence caused by perfluorinated and polyfluoroalkyl compounds such as GenX. According to the technical scheme, the technical problem that drugs which are definite in component, clear in action mechanism, stable in curative effect and capable of pointedly relieving senescence are lacked in the prior art can be solved, and ideal application and popularization prospects are achieved.

The invention discloses a double-gel preparation for relieving lactose intolerance and a preparation method of the double-gel preparation, and belongs to the technical field of dietary nutrition. The double-gel preparation comprises the following components: hydrogel in which beta-galactosidase is embedded and oil gel in which probiotics are embedded, the volume ratio of the hydrogel to the oil gel is (0.2 to 0.8): (0.2 to 0.8). According to the double-gel preparation provided by the invention, synergistic slow release can be realized by adjusting the ratio of water to oil, the activity release rate of beta-galactosidase at the intestinal stage is increased to 50-85%, the release amount of probiotics reaches 5 * 10 < 6 >-10 < 7 > CFU / mL, and the double-gel preparation is remarkably optimized compared with a single gel system. Experiments show that the preparation can quickly relieve lactose intolerance symptoms and improve intestinal flora balance, has both nutrition and functionality, and has wide application potential.

The present invention relates to new improved peptides and dimeric peptides exhibiting beta-galactosidase enzyme activity as well as methods using them for reducing the lactose content of milk-based compositions.

The application belongs to the technical field of biological medicine, and particularly relates to application of SFRP1 in treatment of aortic aging drugs. SFRP1 can induce generation of vascular organoids, significantly antagonize vascular smooth muscle cell senescence induced by angiotensin II and bleomycin, enhance vascular smooth muscle cell activity, improve cell oxidative stress ability, reduce cell beta-galactosidase activity, reduce intracellular calcium deposition level, reduce phenotype conversion and reduce extracellular matrix remodeling. Taxifolin can significantly improve accelerated aortic aging in VSMC-specific Sfrp1 knockout mice. SFRP1 and / or Taxifolin both play an anti-aortic aging role, prevent and / or treat aortic aging related diseases. SFRP1 can be used as a screening target to screen drugs against cell senescence damage.

Provided are lactobacillus delbrueckii subsp. bulgaricus VB183, and a culture apparatus and an application thereof, relating to the field of microorganisms. The accession number of the lactobacillus delbrueckii is CGMCC No. 28204. The lactobacillus delbrueckii of the present invention has advantages such as a high lactose degradation rate, strong beta-galactosidase activity, strong acid and alkali resistance, and strong bile salt resistance, has strong antibacterial ability against common pathogenic bacteria, can be used for relieving lactose intolerance, regulating intestinal flora, and preventing and treating intestinal diseases caused by pathogenic bacteria infection, and has a high application value. The provided lactobacillus delbrueckii subsp. bulgaricus VB183 culture apparatus can be used for batch producing lactobacillus delbrueckii subsp. bulgaricus VB183 fermentation products, which is beneficial for the development of microbial agents, foods, medicines, health care products or feed production apparatuses, and the batch production of commercial products, with a high economic value.

The present invention relates to new improved peptide or dimeric peptides exhibiting betagalactosidase enzyme activity wherein the peptide has a pH optimum at acidic conditions.

The invention discloses bifidobacterium longum CCFM1508 capable of activating a TFEB-HKDC1 autophagy pathway and application of the bifidobacterium longum CCFM1508 in the aspect of colon aging resistance, and belongs to the field of microorganisms. The bifidobacterium longum CCFM1508 provided by the invention has an autophagy regulation capability and can be used for effectively improving colon aging. Through intervention of the bifidobacterium longum CCFM1508, damage to colon tissue of an aged mouse can be remarkably relieved, activity of aging-related beta-galactosidase is inhibited, cell apoptosis is regulated, the level of proinflammatory cytokines is inhibited, oxidative damage degree in the colon tissue is slowed down, transcriptional levels of aging markers p21 and p53 in the colon tissue are remarkably reduced, an autophagy pathway of TFEB-HKDC1 can be activated, and the anti-aging effect is achieved. The autophagy level of the colon tissue is adjusted, and the colon aging resisting effect is achieved. Therefore, the application range of the bifidobacterium longum as probiotics is expanded, and the bifidobacterium longum has a huge application prospect in relieving colon aging.

This invention relates to nanospheres for targeted removal of senescent cells in diabetic wounds and their preparation method. The nanospheres of this invention are galactose-modified PLGA-loaded Fe3O4 nanospheres. Polylactic acid (GAL) is grafted onto the surface of polylactic acid-glycolic acid copolymer (PLGA) microspheres to form a GAL-PLGA complex. Fe3O4 is encapsulated within the complex to form Fe3O4-loaded nanospheres. When the microspheres are engulfed and enter senescent cells in the diabetic wound, they enter lysosomes. Utilizing the increased β-galactosidase activity in senescent cells, the surface GAL can be degraded by the increased activity of β-galactosidase, selectively and slowly releasing the Fe3O4 encapsulated within the microspheres into the senescent cells. The free iron ions generated in the acidic microenvironment of the lysosome induce ferroptosis in the senescent cells, thereby achieving the goal of targeted removal of senescent cells in diabetic wounds.

The invention belongs to the technical field of enzyme engineering, and particularly relates to a method for improving hydrolytic activity of alpha-galactosidase through semi-rational engineering modification of an active site of the alpha-galactosidase and construction of a mutant. According to the invention, based on semi-rational design methods such as sequence alignment, homologous modeling, molecular docking, FoldX energy calculation and the like, the alpha-galactosidase active site from lactobacillus amyloliquefaciens L6 is accurately modified. The mutant enzyme H203P of which the performance is remarkably improved is successfully obtained through directional mutation of active site amino acid residues, the hydrolytic activity of the mutant enzyme H203P reaches 363.95 U / mg and is improved by 2.83 times compared with that of a wild type, the mutant enzyme H203P shows excellent catalytic performance, the enzymatic reaction efficiency is greatly improved, industrial application of alpha-galactosidase is promoted, and the mutant enzyme H203P has a wide application prospect. The method has a wide application prospect and a remarkable economic value in the fields of food processing, feed addition, pharmaceutical and chemical engineering and the like, and is of great significance in promoting the upgrading of related industrial technologies.

The invention discloses an application of MSTN (myostatin) and a downstream target gene thereof as a target spot for detecting and treating liver aging, and belongs to the technical field of biological medicines. The downstream target gene disclosed by the invention is an Slc7a11 gene. The research finds that in mouse primary hepatocytes treated by MSTN recombinant protein for 24 hours, the expression of senescence markers p53, p21, p16 and gamma-H2AX is remarkably up-regulated, and the activity of beta-galactosidase is synchronously enhanced. RNA sequencing analysis shows that cell senescence related gene sets in an MSTN treatment group are remarkably enriched in GO function annotation and GSEA analysis. Differential expression gene heat map analysis further reveals that Slc7a11 is the most significant target gene for down-regulation. Therefore, the MSTN and the downstream target gene Slc7a11 thereof can be used for preparing a reagent and a kit for detecting liver aging; the composition is used for preparing medicines for treating liver aging.

The application provides a high-activity beta-galactosidase mutant, a preparation method and application thereof. In the application, through analysis of a three-dimensional space structure of a complex of a wild-type beta-galactosidase, a substrate and metal ions, and site-directed mutation and combined mutation of amino acid sites related to beta-galactosidase activity and substrate binding, combined with random mutation, a series of beta-galactosidase mutants are successfully obtained, and the enzyme activity of the mutants is greatly improved.

The present invention relates to new improved peptide or dimeric peptides exhibiting beta-galactosidase enzyme activity as well as improved methods for reducing the lactose content in compositions in particular at low temperatures.

The present invention relates to new improved peptide or dimeric peptides exhibiting beta-galactosidase enzyme activity as well as improved methods for reducing the lactose content in compositions in particular at low temperatures.

The present invention relates to a Lactiplantibacillus plantarum) LM1001 (Accession No. KCCM13370P) strain, and a composition for promoting proteolysis, comprising, as an active ingredient, one or more of a culture, lysate, or extract of the strain. The Lactiplantibacillus plantarum LM1001 strain according to the present invention has excellent proteolytic activity, can produce branched-chain amino acids (glutamic acid, tyrosine, alanine, and lysine) that can help produce muscle and prevent muscle loss by degrading whey protein, has excellent β-galactosidase or α-galactosidase activity, and does not have β-glucuronidase activity, and thus the present invention has the effect of ameliorating indigestion, diarrhea, abdominal bloating, and the like due to protein intake.

The present invention relates to isolated polypeptides having lactase activity which is beta-galactosidase activity (EC 3.2.1.108, 3.2.1.23) which show residual activity after ultra high temperature treatment of milk after which the activity increases during incubation at 23°C due to refolding and also relates to polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. Further, the invention relates to a method of producing galacto-oligosaccharides GOS applying the lactases of the invention.

The invention relates to the technical field of biological medicines, and particularly discloses application of a lithium salt in preparation of a product with an effect of promoting ZBP1 activation. Researches show that lithium citrate and lithium carbonate have the following effects: (1) up-regulating expression of skin fibroblasts ZBP1; (2) promoting activation of ZBP1; (3) the activity of beta-galactosidase (SA-beta-Gal) is reduced; (4) a relatively large non-toxic concentration range is shown; therefore, the lithium salt disclosed by the invention plays a role in delaying skin cell aging by up-regulating the expression level of ZBP1 in fibroblasts, promoting ZBP1 activation and / or reducing beta-galactosidase activity. Particularly, the effects of lithium citrate on the aspects of improving ZBP1 expression and relieving cell senescence phenotypes are obviously better than those of lithium carbonate. Therefore, the lithium salt serving as an active ingredient has important application value in preparation of cosmetics or medicines with an anti-aging effect.

The application belongs to the technical field of plant polysaccharides, and discloses a rhizoma atractylodis root polysaccharide and application. The specific structure of the polysaccharide with a molecular weight of 3.7 kD in the rhizoma atractylodis root is determined, the corresponding functional properties are studied, and the application of the polysaccharide with the specific structure in skin anti-aging activity is provided. The anti-aging activity of a product can be improved by promoting the proliferation of keratinocyte HaCAT, inhibiting the beta-galactosidase activity in the keratinocyte HaCAT and ROS active oxygen generation.

The invention discloses application of teprenone in preparation of a medicine for treating children's premature senility (HGPS), and relates to the technical field of biological medicine. Experiments show that teprenone can significantly improve HGPS senescence-related phenotypes: in HGPS model monkey skin fibroblasts, the expression of nuclear fiber layer protein Lamin B1 is up-regulated, the activity of beta-galactosidase is reduced, and the expression of senescence-related secretion phenotype factors is inhibited; in an LmnaG608G mutant HGPS mouse model, the life time is prolonged, Progerin protein expression is down-regulated, phenotypes such as weight loss, skin fibrosis, liver fibrosis and vascular smooth muscle cell deficiency are improved, and the thickness of subcutaneous adipose tissue is increased. As a batch clinical drug, teprenone has a clear safety characteristic and a low side effect risk, existing clinical data can be fully utilized when teprenone is developed as an HGPS treatment drug, the research and development period is shortened, and the teprenone has an important conversion medical value.

This invention relates to a disaccharide exoglycosidase β-agarase with both galactosidase and β-galactosidase activities and its applications, belonging to the field of biotechnology. This invention discloses for the first time a method for developing a β-agarase from *Pseudomonas alterniflora* (…). Pseudoalteromonas An enzyme, ORF0276, and its encoding gene, possessing both galactosidase and disaccharide exonuclease activities, were obtained from the genome of strain Q02 (sp.). This enzyme exhibits strong thermostability, high pH tolerance, and stable physicochemical properties, thus possessing potential for industrial applications. When degrading agar polysaccharide substrates, it can act on the β-1,4 glycosidic bonds of the sugar chains to produce a product primarily composed of neo-agarbiose, which can be used for the industrial preparation of neo-agarbiose (NA2). This research provides a molecular template and theoretical reference for the discovery of such multi-functional tool enzymes.

The purpose of the present invention is to provide a vegetable milk fermented food product having a creamy mouthfeel and having the same smoothness as yogurt, the vegetable milk fermented food product being such that it is possible to user EPS-producing bacteria of a wider variety of types irrespective of whether said bacteria have α-galactosidase activity. A method for manufacturing a vegetable milk fermented food product by inoculating a vegetable-milk-containing fermented raw material with lactic acid bacteria and prompting lactic acid fermentation to occur, wherein the method for manufacturing a vegetable milk fermented food product is characterized in comprising: A) a decomposition step in which α-galactosidase is caused to act on vegetable milk to which a saccharide including galactose bonded by an α-glycoside bond has been added as a constituent sugar, or on vegetable milk containing said saccharide, and the saccharide is hydrolyzed; and B) a fermentation step, performed after or simultaneously with the decomposition step, in which the hydrolyzed saccharide is fermented by lactic acid bacteria having extracellular-polysaccharide-producing capabilities.

This invention relates to an asparagine peptide mixture, its preparation method, and its application in the preparation of products that delay skin aging, belonging to the field of cosmetic technology. The asparagine peptide mixture provided by this invention is an active peptide mixture with a molecular weight <5 kDa, prepared from asparagus root tubers via enzymatic hydrolysis. This asparagine peptide mixture can significantly enhance the vitality of human skin fibroblasts (HSF), promote cell proliferation, and enhance the tissue repair capacity of HSF cells; it can effectively inhibit β-galactosidase activity while increasing the expression level of pre-type I collagen. Furthermore, this invention identifies the top ten most active short peptides in the asparagine peptide mixture through structural identification and activity screening, and demonstrates through molecular docking that the asparagine peptide mixture intervenes in the skin aging process through multiple pathways, providing solid in vitro scientific evidence for the development of natural peptide cosmetics with multiple anti-aging effects from the traditional medicinal plant asparagus.

The invention belongs to the technical field of biological engineering, and particularly relates to a method for improving the activity of beta-galactosidase (LacZ) by fusing a biological aggregate element and a recombinant engineering strain. According to the method disclosed by the invention, a biological aggregate protein element with phase separation capacity is introduced and is subjected to fusion expression with beta-galactosidase, and a target enzyme is induced to form a biological condensed state structure with catalytic activity in cells, so that the biological aggregate is highly enriched in a cell polar region; the local concentration and the reaction efficiency of the beta-galactosidase are effectively improved. According to the strategy provided by the invention, the enzyme activity of the beta-galactosidase is obviously improved and can be about 8 times. The method has the advantages of simplicity and convenience in operation, high universality, capability of being expanded to other functional proteins and the like, is suitable for a biosynthesis system combining high-efficiency expression and activity optimization, and has a wide industrial application prospect.